Results 51 to 60 of about 58,085 (295)
Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2017 Background Chronic inflammation plays a key role in the pathogenesis of intracranial aneurysms (IAs). DPP‐4 (dipeptidyl peptidase‐4) inhibitors have anti‐inflammatory effects, including suppressing macrophage infiltration, in various inflammatory models.
Taichi Ikedo +11 more
semanticscholar +1 more source
Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes [PDF]
, 2017 This is the author accepted manuscript. The final version is available from the publisher via the DOI in this record.The last decade has witnessed the role of dipeptidyl peptidase-4 (DPP-4) inhibitors in producing a conceptual change in early management ...
Paldanius, PM, Strain, WD
core +1 more source
British Journal of Clinical Pharmacology, 2018 The aim of this study was to investigate the putative link between dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use and the risk of fracture in patients with type 2 diabetes.
W. Hou +3 more
semanticscholar +1 more source
Vildagliptin: the first innovative DDP-4 inhibitor
Сахарный диабет, 2010 A review of the main stages of investigation undertaken by Novartis Pharmaceuticals in search of a new molecule for the treatment of type 2 diabetesmellitus, dipeptidyl peptidase-4 (DPP-4) inhibitor (Vildaglyptin). The data on specificity and selectivity
Edvin Villkhauer
doaj +1 more source
Scientific Reports, 2018 Sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors have complementary mode of action. For the meta-analysis comparing the efficacy and safety between SGLT2 inhibitor plus DPP4 inhibitor (SGLT2i/DPP4i) and ...
S. Min +4 more
semanticscholar +1 more source
Teneligliptin in Early Diabetic Kidney Disease: An Observation in Asian Indian Patients with Type 2 Diabetes Mellitus in Real-Life Scenario [PDF]
Journal of Clinical and Diagnostic Research, 2017 Introduction: Teneligliptin is a recently developed Dipeptidyl Peptidase 4 (DPP4) inhibitor. Teneligliptin is suitable for glycaemic control in Type 2 Diabetes Mellitus (T2DM) patients with renal impairment including end stage renal disease.
Kiran Shah
doaj +1 more source
Need an add-on to metformin? Consider this [PDF]
, 2017 Review of: Ou SM, Shih CJ, Chao PW, et al. Effects of clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med.
Lyon, Corey +2 more
core
The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3 [PDF]
, 2018 Aims To evaluate the effect of concomitant dipeptidyl peptidase IV inhibitor (DPPIVi) use on efficacy and safety of insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in people with type 2 diabetes on oral antihyperglycaemic drugs ...
Brito-Sanfiel, Miguel +7 more
core +4 more sources
Journal of Diabetes Investigation, 2018 Dipeptidyl peptidase‐4 inhibitor has been proven to improve glycemic control and β‐cell function in latent autoimmune diabetes in adults (LADA). The potential immune modulation mechanism is still unknown.
Xia Wang +6 more
semanticscholar +1 more source
Терапевтический архивThe review addresses publications on genetic polymorphisms that potentially impact the effectiveness of therapy with hypoglycemic drugs of the dipeptidyl peptidase-4 inhibitor group.
Iuliia G. Samoilova +10 more
doaj +1 more source